Favorable Response to Olaparib in a Patient with Cancer of Unknown Primary Carrying a Germline BRCA1 R71K Mutation

The treatment options for cancer of unknown primary (CUP) are challenging due to the lack of knowledge about the primary sites, often resulting in a poor prognosis. The emerging next-generation sequencing (NGS) technique has provided a reliable approach to facilitate tumor primary site prediction an...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Xiaomeng, Zhao, Shanshan, Li, Xiang, Lv, Li, Chen, Xin, Pan, Evenki, Ou, Qiuxiang, Song, Chen, Sun, Siwen, Zhao, Jinbo, Xu, Lingzhi, Li, Man
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636970/
https://www.ncbi.nlm.nih.gov/pubmed/34866915
http://dx.doi.org/10.2147/OTT.S334847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636970/
https://www.ncbi.nlm.nih.gov/pubmed/34866915
http://dx.doi.org/10.2147/OTT.S334847

Ejemplares similares